Global eClinical Solutions Market Report 2022-2026: Decentralized Clinical Trials, Rising Mobile Health Adoption, and Cloud-based Platforms Lower Costs and Enhance Efficiency
April 29, 2022 05:18 ET | Research and Markets
Dublin, April 29, 2022 (GLOBE NEWSWIRE) -- The "Global eClinical Solutions Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. eClinical solutions are the backbone for...
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 18, 2021 07:00 ET | Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...
Novavax logo
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
February 22, 2021 07:00 ET | Novavax, Inc.
PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing...
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 19, 2021 08:30 ET | Phathom Pharmaceuticals
Topline results expected in second quarter of 2021NDA submission for H. pylori expected in second half of 2021 FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,...
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
October 06, 2020 08:18 ET | Vir Biotechnology, Inc.
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
June 19, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections
April 04, 2019 08:00 ET | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious...
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
April 03, 2018 09:00 ET | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial of...
Innovate Biopharma logo.jpg
Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention
June 06, 2017 08:07 ET | Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., June 06, 2017 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, a leader in developing innovative therapies for autoimmune and inflammatory diseases, will present on its phase 3 drug...
VT Logo
Vital Therapies Provides Corporate Update
January 09, 2017 08:00 ET | Vital Therapies, Inc.
SAN DIEGO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...